A National Registry For Pulmonary Alveolar Proteinosis

Conditions

• Pulmonary Alveolar Proteinosis

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Study Details

The major goal of Part A of this study is to establish a National PAP Registry to help make reliable new research tests available to doctors to improve the diagnosis of PAP, increase awareness and knowledge of PAP, and give patients a 'seat at the table' in planning and conducting PAP research including the clinical testing of several new potential therapies. The major goal of Part B of this study is to define the natural history of autoimmune PAP (aPAP), develop a disease severity score that reflects how aPAP patients feel and function, and to develop and test novel tools to measure the severity of aPAP lung disease. Funding Source - FDA OOPD

Key Dates

Start date

Apr 30, 2015

Status verified

Mar 2026

Primary completion

Dec 31, 2030

Completion

Dec 31, 2030

Study Design

Enrollment

500 participants (estimated)

Arms

• Arm: Registry Participants
  All participants who participate in the National PAP Registry will be put into this cohort and observed over approximately 5 years.

Primary Outcome Measure

DBS card GM-CSF autoantibody levels to diagnose Autoimmune PAP [ Time Frame: 5 years ]

Central Contacts

• Brenna C Carey, Ms, PhD
  513-636-8916
  [email protected]

Locations (1)

Find similar trials in Cincinnati, OH